Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Belgium-based biotechnology company Galapagos has received a E837,000 grant from the Flanders government through the Institute for the Promotion of Innovation by Science and Technology. Galapagos will elucidate the structure of novel drug targets and related small molecules in its bone and joint disease portfolio.
Subscribe to our email newsletter
The two-year project ‘drug discovery for bone and joint protection: structural biology for novel targets and their inhibitors’ focuses on Galapagos’s novel drug targets and the candidate drugs that bind to these targets.
This information will help Galapagos to design potent and selective drugs and thus potentially improve their efficacy to treat bone and joint diseases. Galapagos will collaborate on this project with the Structural Biology Brussels group at the Flanders Institute for Biotechnology (VIB).
Graham Dixon, senior vice president of drug discovery at Galapagos, said: “This grant gives us an opportunity to collaborate with the VIB’s top structural biology group, thereby adding to our drug discovery capabilities. Through this research we aim to progress our understanding of these novel drug targets and accelerate the development of candidate drugs for bone and joint diseases.”